FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to the use of cistus extract in dose of 253 mg/kg to 506 mg/kg as a hepatoprotective agent for therapeutic treatment of cholestatic liver disease and non-alcoholic fatty liver disease. Use of the cistus extract in dose of 253 mg/kg to 506 mg/kg as a hepatoprotective agent for the therapeutic treatment of cholestatic liver disease and non-alcoholic fatty liver disease.
EFFECT: said invention provides an effective agent for therapeutic treatment of said liver diseases.
2 cl, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NALMEFEN, NALTREXONE OR DERIVATIVES THEREOF FOR USE IN TREATING (NON)-ALCOHOLIC STEATOHEPATITIS OR NON-ALCOHOLIC FATTY LIVER DISEASE | 2017 |
|
RU2717677C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANYING METABOLIC SYNDROME | 2018 |
|
RU2686042C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME WITH VITAMIN D DEFICIENCY | 2018 |
|
RU2694842C1 |
| NEW HEPATOPROTECTIVE AGENTS AND METHODS FOR PREPARING THEM | 2023 |
|
RU2815370C1 |
| METHOD OF TREATING PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS ON BACKGROUND OF METABOLIC SYNDROME | 2015 |
|
RU2595815C1 |
| HEPATOPROTECTIVE EFFECT OF LOW MOLECULAR WEIGHT MIMETICS NGF | 2022 |
|
RU2790828C1 |
| USING LACTITOL AND AN ORAL DOSAGE FORM FOR TREATING AND PREVENTING NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2692243C1 |
| HEPATOPROTECTIVE AND ANTIHEPATOTOXIC PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING HEPATIC DISEASES THAT INVOLVES INTRODUCTION OF SAID COMPOSITION | 2008 |
|
RU2381800C1 |
| HEPATOPROTECTIVE AGENTS | 2021 |
|
RU2812847C2 |
| METHOD OF TREATING PATIENTS SUFFERING FROM FIRST STAGE CHOLELITHIASIS | 2012 |
|
RU2519198C2 |
